Last updated: October 25, 2026
Zileuton is a differentiated leukotriene pathway drug with limited current commercial penetration but several formulation opportunities. The strongest product strategy is an optimized extended-release oral dosage form that reduces tablet burden, improves gastrointestinal tolerability, supports adherence, and provides a clean generic or 505(b)(2) regulatory path. Commercial value depends less on new pharmacology than on formulation execution, supply reliability, and positioning against montelukast and inhaled asthma therapies.
What is the commercial status of zileuton?
Zileuton is an oral 5-lipoxygenase inhibitor approved for the prophylaxis and chronic treatment of asthma in adults and children aged 12 years and older. It does not provide rapid relief of acute bronchospasm. The drug reduces leukotriene synthesis rather than blocking the cysteinyl leukotriene receptor, which distinguishes it mechanistically from montelukast and zafirlukast.[1]
The original immediate-release product, Zyflo, was administered as 600 mg four times daily. Zyflo CR, an extended-release 600 mg tablet, reduced administration to 1,200 mg twice daily. The high total daily dose, liver-function monitoring, drug-interaction burden, and competition from once-daily leukotriene receptor antagonists constrained uptake.[1,2]
| Attribute |
Zileuton immediate release |
Zileuton extended release |
| Strength |
600 mg |
600 mg |
| Typical adult dose |
600 mg four times daily |
1,200 mg twice daily |
| Total daily dose |
2,400 mg |
2,400 mg |
| Administration |
Multiple daily doses |
Two administrations daily |
| Primary use |
Chronic asthma control |
Chronic asthma control |
| Acute rescue use |
No |
No |
| Major monitoring issue |
Hepatic transaminases |
Hepatic transaminases |
| Main commercial barrier |
Four-tablet daily schedule |
High tablet burden and monitoring |
The U.S. market is primarily a generic opportunity. The branded products have lost practical commercial prominence, and the regulatory value lies in reliable supply, therapeutic-equivalence positioning, differentiated packaging, and formulation improvements rather than restoration of a premium branded franchise.
What excipient strategy is most suitable for zileuton?
The preferred excipient platform is a hydrophilic matrix extended-release tablet with robust release control across gastric and intestinal pH conditions. The formulation should prioritize dose uniformity, mechanical strength, low moisture sensitivity, and predictable dissolution after food exposure.
Hydrophilic matrix system
A matrix based on hypromellose is the most commercially practical starting point. High-viscosity hypromellose grades can control water penetration and drug diffusion without requiring a complex multiparticulate process.
A candidate platform may include:
- Hypromellose as the primary release-controlling polymer.
- Microcrystalline cellulose as a compression aid and matrix diluent.
- Lactose or an alternative soluble filler, subject to compatibility and moisture control.
- Povidone as a binder where granulation is required.
- Colloidal silicon dioxide to improve powder flow.
- Magnesium stearate at a controlled concentration to limit over-lubrication.
- A film coat based on hypromellose or polyvinyl alcohol for handling, swallowability, and moisture protection.
The exact excipient composition should not simply replicate an existing generic formula. A commercially defensible formulation should produce a differentiated dissolution profile, demonstrate manufacturing robustness, and reduce dependence on a single excipient supplier.
Multiparticulate or coated-pellet platform
A pellet-in-capsule or multiparticulate tablet can provide stronger control of dose release and reduce the risk that tablet damage produces an excessive release rate. This approach may be useful if the drug has variable release behavior in a monolithic matrix.
The disadvantages are higher manufacturing cost, more process steps, and greater scale-up risk. Multiparticulates are more attractive for a branded 505(b)(2) product than for a low-cost ANDA unless the formulation produces a clinically meaningful benefit.
Bilayer or dual-phase dosage form
A bilayer tablet could combine an immediate-release fraction with an extended-release fraction. The concept could provide earlier systemic exposure while maintaining twice-daily dosing. Its commercial value is uncertain because zileuton is not intended for acute symptom relief, and the added complexity may not justify the development cost.
A dual-phase design could still be relevant if pharmacokinetic modeling shows that a lower initial lag time improves exposure consistency or reduces peak-related tolerability issues. That value would require clinical or pharmacokinetic support.
What formulation risks must excipients address?
Zileuton development is dominated by exposure control and tolerability rather than by a simple dissolution target.
Hepatic safety and peak exposure
The FDA label identifies hepatotoxicity as a major risk and recommends baseline and periodic alanine aminotransferase monitoring.[1] An excipient system that creates excessive early release, high peak exposure, or substantial food-dependent variability could weaken the product profile.
The formulation should therefore be tested under:
- Fasted and fed conditions.
- Low, medium, and high agitation conditions.
- Acidic and near-neutral dissolution media.
- Alcohol-induced dose-dumping conditions.
- Storage at elevated temperature and humidity.
- Tablet splitting, crushing, and mechanical stress conditions.
Alcohol-induced dose dumping is particularly relevant for an extended-release product. The finished product should demonstrate that ethanol does not materially accelerate release.
High tablet burden
At 1,200 mg twice daily, patients take two 600 mg tablets per administration. Tablet dimensions, friability, swallowability, and packaging directly affect adherence. A larger single tablet would reduce pill count but may create unacceptable swallowing difficulty and compression defects.
A realistic commercial target is a physically manageable 600 mg tablet with a thin film coat and high tablet hardness. A fixed-dose combination with another asthma medicine could reduce pill burden, but the market and regulatory case would be more difficult because the combination would need to demonstrate clinical relevance and compatibility with the second active ingredient.
Food effects
The original extended-release label contains food-related administration instructions and pharmacokinetic considerations.[2] Excipients that alter wetting, gastric retention, or polymer hydration may change exposure after a high-fat meal.
The development program should compare:
- Fasted administration.
- Standard meal administration.
- High-fat meal administration.
- Administration with common beverages.
- Repeated-dose steady-state exposure.
A formulation with lower food sensitivity could support a differentiated label, but this benefit would generally require a comparative pharmacokinetic study and potentially a 505(b)(2) pathway.
Which excipient technologies offer the strongest commercial opportunity?
| Technology |
Commercial opportunity |
Technical benefit |
Main constraint |
| Hypromellose matrix |
High for generic or lifecycle product |
Low-cost, scalable release control |
Requires dissolution optimization |
| Multiparticulate pellets |
Moderate for differentiated product |
Reduced dose-dumping risk and flexible release |
Higher cost and process complexity |
| Lipid-based system |
Low to moderate |
May improve dissolution for poorly soluble drug |
Food effects and scale-up risk |
| Amorphous solid dispersion |
Selective |
Can improve apparent solubility |
Stability and recrystallization risk |
| Osmotic delivery |
Low |
Strong release control |
High development and manufacturing cost |
| Bilayer tablet |
Moderate |
Immediate plus sustained release |
Limited clinical rationale |
| Abuse-deterrent or tamper-resistant system |
Low |
Potentially stronger physical robustness |
Weak commercial need for this drug |
A conventional hydrophilic matrix is the most likely to produce acceptable return on investment. More complex technologies are justified only if they solve a documented pharmacokinetic or adherence problem.
What generic and 505(b)(2) opportunities exist?
ANDA opportunity
An ANDA for zileuton extended-release tablets would need to establish pharmaceutical equivalence and bioequivalence to the relevant reference product. Critical development work would include:
- Comparative dissolution across multiple media.
- Fed and fasted bioequivalence.
- Dose-dumping evaluation.
- Stability under ICH conditions.
- Demonstration of comparable strength, dosage form, and release characteristics.
- Manufacturing controls for polymer viscosity and granule density.
The principal competitive risks are price erosion, limited market size, and the potential for multiple generic applicants. A low-cost, dependable formulation with reliable API sourcing is more commercially attractive than a technically elaborate formulation without exclusivity.
505(b)(2) opportunity
A 505(b)(2) product could pursue a lower food effect, an alternative dosing schedule, improved swallowability, or a new dosage form. Potential concepts include:
- A once-daily high-strength tablet, subject to pharmacokinetic feasibility.
- A smaller tablet using higher drug loading.
- A sprinkle formulation for patients with swallowing difficulty.
- A gastro-resistant dosage form if local gastric exposure or tolerability supports the approach.
- A lower-peak formulation designed to improve tolerability.
These opportunities would require a clear clinical or pharmacokinetic advantage. A simple excipient substitution generally would not justify a premium product.
What patents protect zileuton formulations?
The original active-ingredient and formulation patent estate is mature. Zileuton was first approved in the 1990s, and the broad composition-of-matter exclusivity period has expired. Any current intellectual-property value is more likely to arise from:
- Specific extended-release matrix compositions.
- Multiparticulate coating structures.
- Manufacturing processes.
- Particle-size or solid-state controls.
- New dosage regimens.
- Combination products.
- Pediatric or other method-of-use claims.
A formulation sponsor should conduct a current search of the USPTO, FDA Orange Book, and relevant international registers before selecting a product architecture. Patent risk will turn on the particular reference-listed product and claims still enforceable in the target jurisdiction, not on the expired original drug patent alone.
What is the FDA and Orange Book status of zileuton?
Zileuton has an established FDA regulatory history as an oral asthma drug. The original branded products were Zyflo and Zyflo CR. The regulatory focus for a current product is likely to be an ANDA or, for a differentiated formulation, a 505(b)(2) application.
The Orange Book review should address:
- Whether the selected reference listed drug remains actively marketed.
- Which dosage form and strength are eligible for reference.
- Whether any listed patents or exclusivity codes remain active.
- Whether the reference product is immediate release or extended release.
- Whether a Paragraph IV certification is required.
- Whether the proposed formulation can rely on the reference product’s safety and efficacy findings.
When does zileuton lose exclusivity?
The drug’s original market exclusivity and broad compound patent protection have expired. Current commercial exclusivity would depend on a new formulation, method-of-use patent, pediatric designation, or other product-specific regulatory event. A generic applicant should not assume that the absence of a live compound patent eliminates all litigation risk, because formulation and manufacturing patents can remain relevant.
What Paragraph IV and litigation risks exist?
Potential Paragraph IV exposure would arise mainly from claims covering extended-release formulations, release profiles, manufacturing methods, or listed methods of use. The risk is lower for a conventional immediate-release generic if no enforceable product-specific patents remain, but the commercial value of that product is also lower because of the historical dosing burden.
A litigation assessment should compare:
| Risk category |
Likely relevance |
| Expired composition patent |
Low |
| Extended-release formulation patent |
Moderate |
| Manufacturing-process patent |
Moderate |
| Method-of-use patent |
Low to moderate |
| Patent on a new dosage regimen |
Product-specific |
| Trademark or trade-dress issue |
Low |
| Regulatory exclusivity |
Low unless a new product is approved |
No reliable commercial conclusion should be drawn from patent expiration alone. The timing of generic entry depends on the selected reference product, Orange Book listings, certification strategy, settlement terms, and whether an applicant receives a 30-month stay after a patent challenge.
How does zileuton compare with competing asthma drugs?
| Product class |
Dosing convenience |
Monitoring burden |
Formulation opportunity |
| Zileuton |
Twice daily for ER product |
Liver-function monitoring |
High |
| Montelukast |
Once daily |
Lower routine monitoring burden |
Moderate |
| Zafirlukast |
Twice daily |
Food and interaction considerations |
Moderate |
| Inhaled corticosteroids |
Product-specific |
Device and technique requirements |
High, but not directly comparable |
| Biologic asthma therapies |
Monthly or less frequent |
Specialist administration |
Limited oral-excipient relevance |
Zileuton’s key disadvantage is operational. It requires oral administration at a high daily dose and has a liver-monitoring requirement. Its advantage is a distinct mechanism that may appeal to selected patients with leukotriene-driven disease, aspirin-exacerbated respiratory disease, or inadequate response to leukotriene receptor antagonism. The commercial opportunity is therefore niche positioning, not broad replacement of montelukast.
What manufacturing and supply-chain barriers matter?
The API must support high drug loading, consistent particle-size distribution, and reliable content uniformity. Extended-release performance may change with API particle size, bulk density, polymorphic form, and granulation conditions.
Priority controls include:
- API particle-size specification.
- Polymorph and crystallinity testing.
- Excipient viscosity and substitution controls.
- Granule density and porosity.
- Compression force and tablet hardness.
- Lubrication time.
- Coating weight gain.
- Dissolution profile by stability time point.
- Supplier qualification for hypromellose and microcrystalline cellulose.
A dual-source strategy for critical excipients can reduce supply disruption. The formulation should avoid unnecessary dependence on specialized polymers or proprietary coating systems unless they create a measurable product advantage.
What licensing and partnership opportunities exist?
Licensing value is most plausible in three areas:
- A regional generic commercialization deal for zileuton extended-release tablets.
- A 505(b)(2) partnership involving a differentiated oral dosage form.
- A contract development and manufacturing agreement with an established modified-release platform.
A branded licensing strategy faces weak market pull unless the product offers a clear advantage in dosing, food administration, liver monitoring workflow, or adherence. A generic partnership can still be attractive where the partner has established payer access, hospital contracts, or regulatory infrastructure in markets with limited competition.
What is the revenue exposure and launch outlook?
The addressable market is constrained by generic competition, alternative asthma therapies, and the need for liver-function monitoring. Revenue would depend on market share rather than high unit pricing.
A practical launch scenario is:
- Initial launch with a standard 600 mg extended-release tablet.
- Supply differentiation through stable API and excipient sourcing.
- Pharmacist and prescriber support focused on substitution and adherence.
- Selective regional licensing rather than global branded commercialization.
- Later development of a lower-burden or food-insensitive formulation if pharmacokinetic data support it.
The highest-value formulation asset would be a once-daily or lower-pill-burden product with comparable safety and exposure. Without that evidence, the product remains primarily a price-competitive generic.
Key Takeaways
- Zileuton is a mature oral asthma drug with limited branded growth potential.
- The strongest excipient strategy is a hypromellose-based extended-release matrix tablet.
- The formulation must control dose dumping, food effects, peak exposure, and tablet size.
- Multiparticulate and 505(b)(2) strategies offer differentiation but carry higher development costs.
- Hepatic monitoring and high daily dose remain the principal commercial barriers.
- Current patent value is more likely to reside in formulation, manufacturing, or regimen claims than in the original compound patent.
- A generic launch is more commercially credible than a premium branded relaunch.
- The most attractive lifecycle concept is a lower-burden, food-insensitive, exposure-controlled formulation.
FAQs
Can zileuton be formulated as a once-daily tablet?
Possibly, but once-daily development would require pharmacokinetic evidence showing adequate 24-hour exposure without unacceptable peak concentrations or loss of efficacy. The high total daily dose creates a substantial tablet-size and release-control challenge.
Which polymer is most suitable for zileuton extended release?
Hypromellose is the most practical first-line polymer because it is scalable, broadly available, and compatible with hydrophilic matrix technology. Polymer viscosity, loading level, and granule structure require optimization.
Is an enteric-coated zileuton product commercially attractive?
The opportunity is limited unless enteric protection produces a documented tolerability or exposure benefit. Enteric coating would add process complexity and could delay drug release without solving the primary adherence problem.
Could zileuton be developed as a pediatric liquid?
A liquid or multiparticulate pediatric product could address swallowing limitations, but pediatric use would require an appropriate dose rationale, stability data, palatability work, and regulatory support. The existing approved use is for patients aged 12 years and older.[1]
Does zileuton have biosimilar risk?
No. Zileuton is a small-molecule drug, not a biologic. Competitive entry would occur through generic or 505(b)(2) pathways rather than biosimilar approval.
References
-
U.S. Food and Drug Administration. (2012). Zyflo CR (zileuton extended-release tablets) prescribing information. FDA.
-
U.S. Food and Drug Administration. (1997). Zyflo (zileuton tablets) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
-
National Library of Medicine. (2024). DailyMed: Zileuton drug labels. U.S. National Library of Medicine.
